Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study evaluated the ocular surface tolerability of the prostaglandin analogues
bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004%
(Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously
treated with Xalatan® who have open-angle glaucoma or ocular hypertension.